Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1793 results
May 2015
-
Could umbilical cords yield more stem cells for life-saving transplants?
Umbilical cords are a potentially life-saving source of blood stem cells for people with leukemia and other diseases. But there aren’t enough cells to meet demand. Now an experimental treatment offers hope for a solution.
-
Media ReleaseNovartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumorsStudy in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met primary endpoint[1] Full results will be submitted for presentation at…
-
Media ReleaseNovartis announces two positive US phase III programs in COPD for QVA149 and NVA237QVA149 improved lung function, breathlessness and health-related quality of life in moderate-to-severe COPD patients, according to EXPEDITION trial results[1]-[7] GEM 1 & 2 studies…
-
Letters to my younger self: Female scientists share their wisdom
Accomplished female scientists at Novartis share their wisdom born from difficult moments in life.
-
Media ReleaseNovartis lung cancer drug Zykadia® gains EU approval, providing new therapy for certain patients with ALK+ NSCLCZykadia (ceritinib) is the first treatment option approved for patients in Europe with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib Marketing authorization was based on…
April 2015
-
Media ReleaseNovartis announces Phase III study of Arzerra® met primary endpoint of improved progression-free survival in patients with relapsed CLLPositive top-line results seen with Arzerra plus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) patients when initial treatment stopped working CLL is the most…
-
Media ReleaseNovartis a affiché, au T1[1], une forte progression de ses ventes (tcc), une hausse importante de sa marge (tcc) et une innovation très dynamique; avec un portefeuille désormais mieux cibléVentes, résultat opérationnel core[2] et BPA core (tcc[2]) des activités poursuivies[1] en hausse au T1 Chiffre d'affaires net s'élevant à USD 11,9 milliards (-7%, +3% tcc)]2] Résultat…
-
Media ReleaseNovartis erzielt im ersten Quartal[1] Umsatzsteigerungen (kWk), deutlich höhere Margen (kWk) und beachtliche Innovationen - jetzt mit einem stärker fokussierten PortfolioDie fortzuführenden Geschäftsbereiche[1] steigern im ersten Quartal den Umsatz, das operative Kernergebnis[2] und den Kerngewinn pro Aktie (kWk[2]) Der Nettoumsatz beläuft sich auf USD 11,9…
-
Media ReleaseNovartis delivered sales growth (cc), significant margin expansion (cc) and strong innovation in Q1[1]; now with a more focused portfolioContinuing operations[1] saw sales, core[2] operating income and core EPS grow (cc[2]) in Q1 Net sales were USD 11.9 billion (-7%, +3% cc)[2] Operating income was USD 2.8 billion (-1%, +15% cc)…
-
Media ReleaseNovartis celebrates 19th annual Community Partnership Day with more than 27,000 associates volunteering in their local communitiesMore than 27,000 Novartis associates worldwide dedicate an estimated 200,000 hours to volunteer with charitable causes in their communities Community Partnership Day symbolizes the company'…
-
Nurturing the life science ecosystem
-
Media ReleaseData at AAN showed Gilenya® high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patientsNew FREEDOMS/FREEDOMS II sub-group analysis showed Gilenya-treated patients were six-times more likely to achieve 'no evidence of disease activity (NEDA4)' vs placebo NEDA4 is based on four…
Pagination
- ‹ Previous page
- 1
- …
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- …
- 150
- › Next page